Dannel Yeo

Dr. Dannel Yeo


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
DYDannel Yeo
Dannel Yeo
CGCaroline Giardina
Caroline Giardina
PSPayal Saxena
Payal Saxena
JRJohn E.J. Rasko
John E.J. Rasko
Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes.

Verified
Journal Article
Open access
PDF file
DYDannel Yeo
Dannel Yeo
ABAlthea Bastian
Althea Bastian
HSHeidi Strauss
Heidi Strauss
PSPayal Saxena
Payal Saxena
PGPeter Grimison
Peter Grimison
JRJohn E.J. Rasko
John E.J. Rasko
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type, characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited therapeutic response to standard chemotherapy. Circulating tumor cells (CTCs) are a rare subset of tumor cells found in the blood of cancer patients. CTCs has the potential utility for screening, early and definitive diagnosis, prognostic and predictive assessment, and offers the potential for personalized management. However, a gold-standard CTC detection and enrichment method remains elusive, hindering comprehensive comparisons between studies. In this review, we summarize data regarding the utility of CTCs at different stages of PDAC from early to metastatic disease and discuss the molecular profiling and culture of CTCs. The characterization of CTCs brings us closer to defining the specific CTC subpopulation responsible for metastasis with the potential to uncover new therapies and more effective management options for PDAC.

4 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DYDannel Yeo
Dannel Yeo
Laura CastellettiLaura Castelletti
Laura Castelletti
Nico Van ZandwijkNico Van Zandwijk
Nico Van Zandwijk
JRJohn E.J. Rasko
John E.J. Rasko
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options and poor prognosis. MPM originates from the mesothelial lining of the pleura. Mesothelin (MSLN) is a glycoprotein expressed at low levels in normal tissues and at high levels in MPM. Many other solid cancers overexpress MSLN, and this is associated with worse survival rates. However, this association has not been found in MPM, and the exact biological role of MSLN in MPM requires further exploration. Here, we discuss the current research on the diagnostic and prognostic value of MSLN in MPM patients. Furthermore, MSLN has become an attractive immunotherapy target in MPM, where better treatment strategies are urgently needed. Several MSLN-targeted monoclonal antibodies, antibody–drug conjugates, immunotoxins, cancer vaccines, and cellular therapies have been tested in the clinical setting. The biological rationale underpinning MSLN-targeted immunotherapies and their potential to improve MPM patient outcomes are reviewed.

19 August 2013 in Journal of Investigative Surgery
Verified
Journal Article
Closed access
MNMehrdad Nikfarjam
Mehrdad Nikfarjam
DYDannel Yeo
Dannel Yeo
HHHong He
Hong He
GBGraham Baldwin
Graham Baldwin
TFTheodora Fifis
Theodora Fifis
CCChristopher Christophi
Christopher Christophi
Background: Pancreatic adenocarcinoma has an extremely poor prognosis. The use of appropriate in vivo models is essential in devising methods to improve treatment outcomes. Methods: A pancreatic adenocarcinoma model based on tumor injection into the pancreatic head was compared with a pancreatic tail injection model in C57/BL6 mice. The murine pancreatic adenocarcinoma cell line PAN02, dispersed in MatrigelTM, was used for tumor induction. Results: Tumors developed in all animals in both models. Tumor size was more consistent within the pancreatic tail group at 20 days following induction, with no evidence of metastatic disease. Animals in the pancreatic head injection group showed signs of reduced health by 20 days following injection and developed jaundice. Microscopic liver metastases were noted in some of these animals at this time point. The overall survival of animals at 40 days following tumor induction was significantly lower in the pancreatic head injection group (0% vs. 35%; p < .001). Multiple liver metastases were noted in five of 10 (50%) animals in the head injection group, without evidence of peritoneal metastases. In the pancreatic tail injection group, 18 of 20 (90%) animals had multiple peritoneal metastases, and nine of 20 (45%) animals had evidence of isolated liver deposits. Tumors in both regions of the pancreas had similar histologic characteristics, with a dense fibrotic stroma at the interface between the tumor and the normal pancreas. Conclusion: Pancreatic head and tail orthotopic cancer models produce consistent tumors, but the patterns of tumor spread and survival differ according to the site of injection.

14 November 2024 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
APAnthony Pirrello
Anthony Pirrello
MKMurray Killingsworth
Murray Killingsworth
KSKevin Spring
Kevin Spring
JRJohn E.J. Rasko
John E.J. Rasko
DYDannel Yeo
Dannel Yeo
Cancer-associated macrophage-like cells (CAMLs) are myeloid-lineage cells associated with cancer-derived material that are detectable in the blood. In addition to circulating tumor cells, CAMLs are a promising liquid biopsy biomarker which may assist with prognostication for patient stratification and monitoring response to chemotherapy and radiotherapy in solid tumors. CAMLs have been detected in blood samples from patients with various tumors including lung, pancreas, breast, oesophageal, and colorectal cancers, and to date have not been detected in healthy individuals. However, the optimal method of detection, their origin, function in the circulation, and ultimate utility have not been fully elucidated. This review provides an overview of CAML-related studies and explores their future potential to guide clinical decision-making.

13 February 2024 in Cytotherapy
Verified
Journal Article
Closed access
GCGerard J. Chu
Gerard J. Chu
Charles BaileyCharles Bailey
Charles Bailey
RNRajini Nagarajah
Rajini Nagarajah
OLOliver Liang
Oliver Liang
CMCynthia Metierre
Cynthia Metierre
JRJohn E.J. Rasko
John E.J. Rasko